



## **SurModics to Showcase Five Papers at the Association for Research in Vision and Ophthalmology Meeting**

April 26, 2005

EDEN PRAIRIE, Minn., Apr 26, 2005 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that five papers will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Fort Lauderdale, Florida, May 1-5, 2005. The five papers relate to the platform technologies SurModics acquired from InnoRx, Inc. in January of this year. Included will be a discussion by Signe Erickson Varner, Ph.D., former Assistant Professor of Ophthalmology at the Doheny Eye Institute and the current Director of R&D for SurModics' ophthalmology business unit.

The InnoRx technology, specifically the drug-coated intravitreal implant which serves as the company's lead product in the ophthalmology arena, targets age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of blindness. The SurModics presentations will explore the results of recent animal studies including the discussion of three papers specifically focused on the implant and two papers evaluating subretinal drug delivery.

Dr. Eugene de Juan, Jr., retinal surgeon, Founder of InnoRx and clinical consultant to SurModics, commented, "We are very pleased to have a strong scientific presence at this year's meeting. The research that will be presented at ARVO highlights the significant progress we have made in SurModics' ocular program and reflects our continued focus on delivering therapy to the eye on a sustained basis." He continued, "We were encouraged by the positive outcomes of these studies and the success we have seen in the animal trials in regards to safety. We believe this technology platform shows great promise and are excited by the opportunities inherent in its continued development."

About SurModics, Inc.

SurModics, Inc., a leading provider of surface modification and drug delivery solutions, licenses its proprietary technologies to medical device, diagnostics, and biotechnology companies around the world. A significant portion of SurModics' revenue is generated through royalties on the sale of coated products. SurModics' Internet address is [www.surmodics.com](http://www.surmodics.com). The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.

Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. Factors that may cause actual results to differ from the forward-looking statements include those described in the "Risk Factors" and other sections of SurModics' filings with the Securities and Exchange Commission. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: SurModics, Inc.

SurModics, Inc.  
Phil Ankeny, 952-829-2700